Skip to main content
Journal of Analytical Science and Technology

Table 2 Recovery, matrix effect, and process efficiency of alpelisib and the internal standard in mouse and human plasma (mean ± SD, n = 3)

From: Bioanalysis of alpelisib using liquid chromatography–tandem mass spectrometry and application to pharmacokinetic study

 

Nominal concentration (ng/mL)

LQC

MQC

HQC

3

150

1600

(A) Alpelisib

   

Mouse plasma

  Recovery (%)a

90.8 ± 1.3

91.0 ± 0.3

100 ± 0

  Matrix effect (%)b

99.9 ± 1.5

96.8 ± 0.7

99.8 ± 0.8

  Process efficiency (%)c

92.2 ± 1.4

88.4 ± 0.7

98.9 ± 0.6

Human plasma

  Recovery (%)

93.1 ± 0.7

91.1 ± 0.3

101 ± 1

  Matrix effect (%)

101 ± 1

96.8 ± 0.3

97.3 ± 0.4

  Process efficiency (%)

94.7 ± 1.0

88.0 ± 0.7

98.5 ± 1.6

 

Nominal concentration (ng/mL)

300

(B) Internal standard (enzalutamide)

Mouse plasma

  Recovery (%)

102 ± 2

  

  Matrix effect (%)

99.8 ± 1.3

  

  Process efficiency (%)

100 ± 1

  

Human plasma

  Recovery (%)

98.0 ± 2.2

  

  Matrix effect (%)

99.8 ± 1.5

  

  Process efficiency (%)

96.6 ± 1.9

  
  1. aMatrix effect (%) = mean peak area of an analyte added post-precipitation (set 2)/mean peak area of an analyte in neat analyte solution (set 1) × 100
  2. bRecovery (%) = mean analyte peak area of an analyte added before precipitation (set 3)/mean peak area of an analyte added post-precipitation (set 2) × 100
  3. cProcess efficiency (%) = mean analyte peak area of an analyte added before precipitation (set 3)/mean peak area of an analyte in neat analyte solution (set 1) × 100
Back to article page